Skip to main content
Erschienen in: Reactions Weekly 1/2019

01.11.2019 | Case report

Dasabuvir/ombitasvir/paritaprevir/ritonavir

Various toxicities: 2 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Londono M-C, et al. Effectiveness, safety/tolerability of OBV/PTV/r +/- DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice-Vie-KinD study. PLOS One 14: No. 9, 24 Sep 2019. Available from: URL: http://doi.org/10.1371/journal.pone.0221567 - SpainCrossRef Londono M-C, et al. Effectiveness, safety/tolerability of OBV/PTV/r +/- DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice-Vie-KinD study. PLOS One 14: No. 9, 24 Sep 2019. Available from: URL: http://​doi.​org/​10.​1371/​journal.​pone.​0221567 - SpainCrossRef
Metadaten
Titel
Dasabuvir/ombitasvir/paritaprevir/ritonavir
Various toxicities: 2 case reports
Publikationsdatum
01.11.2019
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-019-70967-1

Weitere Artikel der Ausgabe 1/2019

Reactions Weekly 1/2019 Zur Ausgabe

Case report

Pembrolizumab

Case report

Pembrolizumab

Case report

Lisinopril

Case report

Multiple drugs

Case report

Dapsone

Case report

Fludrocortisone